Liver cancer cases are projected to nearly double worldwide by 2050, driven largely by hepatitis infections, according to recent studies and health organizations. The World Health Organization (WHO) has classified hepatitis D as carcinogenic to humans, similar to hepatitis B and C, highlighting its role in causing liver cancer in individuals already infected with hepatitis B. Hepatitis B and C medicines can reduce the risk of liver cancer, and early diagnosis and treatment are critical for saving lives. Despite this, only one in three people living with hepatitis B are aware of their infection, and more than half do not receive adequate care to monitor liver health or determine the need for antiviral treatment. In New York City, disparities in newly reported chronic hepatitis B and C cases exist across gender, race, ethnicity, neighborhood, poverty level, and age, underscoring ongoing inequities even in areas with advanced healthcare. Efforts such as the SF Hep B Free initiative aim to unite and empower hepatitis B advocates across the U.S. and beyond. The Lancet reports that hepatocellular carcinoma (HCC), which accounts for about 80% of global liver cancer cases, is increasing, and a new Commission has issued evidence-based recommendations to reduce the global HCC burden. Health plans now cover screenings for hepatitis B and C, emphasizing the importance of preventive care.